Launching the most advanced transgenic animal platform for human antibody drug discovery
SAN DIEGO, CA / ACCESS Newswire / September 2, 2025 / Ablexis, LLC, a biopharmaceutical company focused on advancing human antibody drug discovery through provision of its AlivaMab Mouse technology, today announced the launch of AlivaMab Mouse-NGX, a next-generation suite of advanced transgenic mice that expand both the number and human variable region diversity of antigen-specific antibodies while retaining their requisite drug-like properties.
“AlivaMab Mouse-NGX strains represent a major evolution of our platforms relative to earlier generations of AlivaMab Mouse, which already outperformed other transgenic models and have yielded at least 18 antibodies entered into clinical trials,” said Larry Green, Ph.D., Chief Executive Officer of Ablexis. “Our validation tests confirm that AlivaMab Mouse-NGX strains produce up to six-times the number of antigen-specific antibodies while also exhibiting expansion of combinatorial and junctional diversity versus comparator platforms. AlivaMab Mouse-NGX strains set a new benchmark for success in B-cell- and NGS-based human antibody drug discovery,” Dr. Green continued.
The AlivaMab Mouse platform is available for use in-house by Ablexis’ licensees or exclusively for service provision through AlivaMab Biologics, including access on a license-free, milestone- and royalty-free basis.
About Ablexis, LLC
Ablexis, LLC creates and offers AlivaMab Mouse, a growing suite of unique, patented next generation transgenic mice, as a foundational platform for successful human antibody drug discovery and development. Dozens of companies, including 13 of the world’s top 25 global pharmaceutical companies, public and private biotechnology companies, and other entities have licensed AlivaMab Mouse for their antibody drug discovery. Ablexis’ sister company, AlivaMab Biologics provides an integrated antibody therapeutic discovery and engineering platform using the AlivaMab Mouse technologies. For more information, please contact us at info@ablexis.com.
###
Media Contact:
Maya Tanaka
mtanaka@ablexis.com
SOURCE: Ablexis, LLC
View the original press release on ACCESS Newswire
BUENOS AIRES, ARGENTINA, MARCH 31, 2026 ― When the Teatro Colón opens its doors to…
Creative Technology Group, Inc. (CT), the NEP Live Events group, has invested in multiple Analog…
AiGS will leverage n8n's platform to deliver future-ready automation solutions that streamline operations and unlock…
First-in-class metal-modulating epigenetic therapy targeting iron-dependent pathways with preclinical efficacy and a favorable GLP safety…
PHOENIX, AZ / ACCESS Newswire / March 31, 2026 / 1606 Corp. (OTCID:CBDW) ("1606" or…
Company Invites Investors to Submit Questions to be Answered on the Webcasted Earnings Call TORONTO,…